Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae type b vaccine
- Development stage
- Unknown
- Lead developer
- Zhifei Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a pentavalent combination vaccine developed by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd, a subsidiary of Chongqing Zhifei Biological Products. The vaccine is designed to provide active immunization against five major childhood diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and invasive infections caused by Haemophilus influenzae type b (Hib). It utilizes a "component" acellular pertussis technology, which involves the use of individually purified and well-defined pertussis antigens (such as pertussis toxoid and filamentous hemagglutinin) rather than traditional co-purified mixtures. This approach is intended to improve manufacturing consistency and potentially reduce adverse reactions. The vaccine is currently in Phase III clinical development in China, where it is being evaluated for safety and immunogenicity in infants, often compared against established pentavalent vaccines like Pentaxim.
- Other names
- DTaP-IPV/Hib vaccineZhifei Lvzhu pentavalent vaccine
02
Targets
FHA (Filamentous hemagglutinin)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae type b vaccine.